Development of an in vitro platform for transesophageal echocardiographic and color Doppler hemodynamic assessments of left atrial appendage occlusion devices

Back

ESC Professional Premium Access

Development of an in vitro platform for transesophageal echocardiographic and color Doppler hemodynamic assessments of left atrial appendage occlusion devices

Session: Cardioversion, antiarrhythmics and antithrombotic management of atrial fibrillation

Topic: Device Treatment

Speaker: Mr Z. Zhong (Munich, DE)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Mr Zhaoyang Zhong

Technical University of Munich, Munich (Germany)

0 follower

5 more presentations in this session

A genetic polymorphism on chromosome 4q25 (rs17570669_T) may predict atrial fibrillation recurrence after successful electrical cardioversion

Speaker: Professor T. Ulus (Eskisehir, TR)

Efficacy and safety of antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation depending on gender: a subanalysis of CANT II Study

Speaker: Associate Professor M. Wybraniec (Katowice, PL)

Intravenous infusion of potassium/magnesium solution for the treatment of postoperative atrial fibrillation after coronary artery bypass graft: a randomized, double-blinded, parallel controlled trial

Speaker: Doctor F. Masoudkabir (Tehran, IR)

Efficacy of bepridil as a periprocedural support drug in atrial fibrillation patients with left ventricular systolic dysfunction undergoing catheter ablation

Speaker: Mr K. Okabe (Fukuoka, JP)

Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program

Speaker: Doctor I. Diemberger (Bologna, IT)

Access

Abstract

Slides

Access the full session

Cardioversion, antiarrhythmics and antithrombotic management of atrial fibrillation

Speakers: Mr Z. Zhong, Professor T. Ulus, Associate Professor M. Wybraniec, Doctor F. Masoudkabir, Mr K. Okabe...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Development of an in vitro platform for transesophageal echocardiographic and color Doppler hemodynamic assessments of left atrial appendage occlusion devices

About the speaker

Mr Zhaoyang Zhong

5 more presentations in this session

A genetic polymorphism on chromosome 4q25 (rs17570669_T) may predict atrial fibrillation recurrence after successful electrical cardioversion

Efficacy and safety of antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation depending on gender: a subanalysis of CANT II Study

Intravenous infusion of potassium/magnesium solution for the treatment of postoperative atrial fibrillation after coronary artery bypass graft: a randomized, double-blinded, parallel controlled trial

Efficacy of bepridil as a periprocedural support drug in atrial fibrillation patients with left ventricular systolic dysfunction undergoing catheter ablation

Persistence to edoxaban treatment in patients with atrial fibrillation: Analysis from the Global ETNA-AF program

Access the full session

Cardioversion, antiarrhythmics and antithrombotic management of atrial fibrillation

About the event

ESC Congress 2023

ESC 365 is supported by